Pacific Biosciences/PACB

$1.46

3.57%
-
1D1W1MYTD1YMAX

About Pacific Biosciences

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Ticker

PACB

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Christian Henry

Employees

796

Headquarters

Menlo park, United States

PACB Metrics

BasicAdvanced
$759.64M
Market cap
-
P/E ratio
-$1.21
EPS
1.88
Beta
-
Dividend rate
$759.64M
1.87994
$14.55
$2.81
8.25M
7.809
7.212
127.226
127.296
-22.45%
-17.46%
-48.53%
-19.45%
3.788
1.082
56.29%
13.4%
36.47%

What the Analysts think about PACB

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
342.47% upside
High $20.00
Low $2.00
$1.46
Current price
$6.46
Average price target

PACB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-140.65% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$58.3M
4.86%
Net income
$-82M
22.75%
Profit margin
-140.65%
17.07%

PACB Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.7%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.36
-$0.28
-$0.26
-$0.31
-
Expected
-$0.33
-$0.32
-$0.33
-$0.29
-$0.28
Surprise
8.27%
-12.67%
-20.76%
8.7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pacific Biosciences stock?

Pacific Biosciences (PACB) has a market cap of $759.64M as of April 19, 2024.

What is the P/E ratio for Pacific Biosciences stock?

The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of April 19, 2024.

Does Pacific Biosciences stock pay dividends?

No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Pacific Biosciences dividend payment date?

Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.

What is the beta indicator for Pacific Biosciences?

Pacific Biosciences (PACB) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Pacific Biosciences stock price target?

The target price for Pacific Biosciences (PACB) stock is $6.46, which is 342.47% above the current price of $1.46. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pacific Biosciences stock

Buy or sell Pacific Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing